tiprankstipranks
Royalty Pharma PLC (RPRX)
NASDAQ:RPRX

Royalty Pharma (RPRX) Income Statement

652 Followers

Royalty Pharma Income Statement

Last quarter (Q4 2023), Royalty Pharma's total revenue was $596.07M, an increase of 5.36% from the same quarter last year. In Q4, Royalty Pharma's net income was $494.34M. See Royalty Pharma’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ 2.30B$ 2.35B$ 2.24B$ 2.29B$ 2.12B$ 1.81B
Cost of Revenue
------
Gross Profit
$ 2.35B$ 2.35B$ 2.24B$ 2.29B--
Operating Expense
$ 301.75M$ 301.75M$ -1.31B$ 405.91M$ 526.95M$ -808.92M
Operating Income
$ 1.85B$ 1.49B$ 922.89M$ 1.88B$ 1.60B$ 2.62B
Net Non Operating Interest Income Expense
$ -345.46M$ -747.84M$ -109.63M$ -112.61M$ -128.68M$ -246.24M
Other Income Expense
$ -352.77M$ -395.13M$ 583.20M$ 76.91M$ 235.24M$ 84.49M
Pretax Income
$ 1.70B$ 1.70B$ 230.06M$ 1.24B$ 1.70B$ 2.46B
Tax Provision
----$ 0.00$ 0.00
Earnings From Equity Interest Net Of Tax
$ 28.88M$ 28.88M$ -8.97M$ -19.49M--
Net Income Common Stockholders
$ 1.13B$ 1.13B$ 42.83M$ 619.73M$ 495.20M$ 2.35B
Basic EPS
$ 2.54$ 2.54$ 0.10$ 1.49$ 1.32$ 3.35
Diluted EPS
$ 2.25$ 2.53$ 0.10$ 1.49$ 1.32$ 3.35
Basic Average Shares
$ 1.79B$ 447.60M$ 437.96M$ 414.79M$ 375.44M$ 354.18M
Diluted Average Shares
$ 2.41B$ 602.90M$ 437.97M$ 414.80M$ 375.44M$ 354.18M
Dividend Per Share
$ 0.80$ 0.80$ 0.76$ 0.68$ 0.30-
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 301.75M$ 301.75M$ 410.08M$ 405.91M$ 526.95M$ -808.92M
Net Income From Continuing And Discontinued Operation
$ 1.30B$ 1.13B$ 42.83M$ 619.73M$ 975.04M$ 2.35B
Normalized Income
$ 958.65M$ 1.36B$ 808.68M-$ 751.44M$ 2.23B
Interest Expense
----$ 157.06M$ 268.57M
EBIT
$ 1.87B$ 1.89B$ 418.02M$ 1.35B$ 1.86B$ 2.73B
EBITDA
$ 1.70B$ 1.89B$ 423.69M$ 1.38B$ 1.88B$ 2.75B
Currency in USD

Royalty Pharma Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis